Sotera Health Company SHC
15.98 USD -1.76 (-9.95%)
Nov 3, 2026, 3:57 PM EST
15.90 Day range 17.28
13.09 52-week range 19.85
- YTD
- -9.44%
- 1 year
- -3.82%
Analyst view
Consensus: buy
Buy
Price target (mean) 22.61 +41.5% upside
Now 15.98
- Target (low)
- 17.00
- Target (mean)
- 22.61
- Target (high)
- 25.00
Ratings (0m) 10 8 buy · 1 hold · 1 sell
- Strong buy3
- Buy5
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.26864 | 0.26 – 0.27 | 0.26 | +3.3% | 319.88M | +2.8% | 10 |
| Next quarter | 0.27557 | 0.27 – 0.28 | 0.26 | +6.0% | 325.60M | +7.3% | 10 |
| Current year | 0.98383 | 0.978 – 0.99 | 0.86 | +14.4% | 1.25B | +7.2% | 10 |
| Next year | 1.07 | 1.03 – 1.13 | 0.98383 | +9.3% | 1.32B | +5.9% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Downgrade | Neutral | Underweight |
| Aug 7, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Aug 7, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Jun 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 5, 2026 | Goldman Sachs | Initiated | Buy | Buy |
| May 6, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2026 | Citigroup | Maintained | Buy | Buy |
| Jan 9, 2026 | Piper Sandler | Upgrade | Neutral | Overweight |
| Dec 18, 2025 | William Blair | Initiated | — | Outperform |
| Nov 13, 2025 | BMO Capital | Initiated | — | Outperform |
| Nov 5, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 5, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 5, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 2, 2025 | Barclays | Maintained | Overweight | Overweight |
| Jun 24, 2025 | Barclays | Maintained | Overweight | Overweight |
| May 5, 2025 | Goldman Sachs | Upgrade | Neutral | Buy |
| Apr 23, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Apr 10, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 28, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 18, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 21, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Nov 6, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 6, 2024 | Barclays | Maintained | Overweight | Overweight |
| Aug 6, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| May 21, 2024 | Piper Sandler | Initiated | — | Neutral |
| Apr 10, 2024 | Barclays | Maintained | Overweight | Overweight |
| Apr 3, 2024 | Citigroup | Upgrade | Neutral | Buy |
